● LIVE
Updated 10d ago
· 7 sources tracked
New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks
A new oral GLP-1 medication has demonstrated weight loss of up to 12% over 36 weeks. Meanwhile, Medicare is launching a pilot program to expand access to drugs like Zepbound and Wegovy. This initiative aims to make weight loss medications more affordable for some beneficiaries.
What changed
New data on oral GLP-1 efficacy and the start of a Medicare access pilot are now available.
Live updates
-
New Oral GLP-1 Drug Shows 12% Weight Loss in 36 Weeks
confidence 90%A new oral GLP-1 medication has demonstrated weight loss of up to 12% over 36 weeks. Meanwhile, Medicare is launching a pilot program to expand access to drugs like Zepbound and Wegovy. This initiative aims to make weight loss medications more affordable for some beneficiaries.
What's confirmed:
- A new oral GLP-1 drug delivers up to 12% weight loss in 36 weeks.
- A Medicare pilot began Wednesday to broaden access to medications including Zepbound and Wegovy.
Still unconfirmed:
- The Bridge program may enable affordable access for some Medicare beneficiaries.
- Unique risks exist for people over 65 using GLP-1s.